Shanghai Ruidao Medical Technology
Irreversible electroporation systems for non-thermal tumor ablation.
| Date | Investors | Amount | Round |
|---|---|---|---|
* | CNY100m | Series A | |
| Total Funding | 000k | ||
Shanghai Ruidao Medical Technology Co., Ltd. is a medical device company established in September 2016, specializing in irreversible electroporation (IRE) technology for tumor treatment. The company's founder is Sun Zhu.
The core of Ruidao Medical's offering is its composite steep pulse treatment equipment, a form of non-thermal ablation technology sometimes referred to as NanoKnife. This technology applies high-voltage, ultra-short electrical pulses to the cell membranes of tumors, creating permanent nano-sized pores that lead to cell apoptosis without affecting surrounding healthy tissue structures like blood vessels and nerves. This method is a distinct alternative to traditional thermal ablation techniques such as radiofrequency, microwave, or cryoablation. The company's flagship product was the first domestically developed composite steep pulse treatment device approved for prostate cancer therapy. Following its initial product success, the company has expanded its focus to other applications, including benign prostatic hyperplasia, liver cancer, and pulsed-field ablation (PFA) for atrial fibrillation. In July 2022, its pulsed-field ablation device was granted entry into the National Medical Products Administration's (NMPA) special review process for innovative medical devices.
Ruidao Medical has established a comprehensive intelligent solution for focal prostate cancer therapy that integrates disease diagnosis, surgical planning, and energy ablation, which includes a prostate puncture navigation robot and a cloud data planning platform. The company has secured significant funding to advance its research, development, and clinical trials. In September 2021, it completed a Series A funding round of CNY 100 million (approximately $15.5 million) led by Detong Capital. This was followed by a Series A+ round in February 2023, raising over CNY 100 million, led by Paradise Silicon Valley and joined by Detong Capital and Qianzhan Capital.
Keywords: irreversible electroporation, IRE, tumor ablation, pulsed-field ablation, non-thermal ablation, prostate cancer treatment, medical devices, composite steep pulse, oncology, atrial fibrillation, NanoKnife, PFA systems, soft tissue ablation, benign prostatic hyperplasia, liver cancer treatment, surgical oncology, medical technology, urology, cardiology.